foxo4 dri senolytic peptide human trial 2024 2025 Buy FOXO4-DRI (Proxofim) Senescent cells as a target
Senescent cells as a target for anti aging interventions: From senolytics to immune therapies PMC Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Full article: Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4



